Boston, US-based PureTech Health has appointed Dr Atul Pande as its new chief medical officer, responsible for the firm’s pipeline in immune, nervous and gastro-intestinal systems.
Dr Pande was formerly senior vice president and head of neuroscience at GlaxoSmithKline, where he also served as a senior advisor in its R&D division.
Prior to this, he was chief medical officer at Cenerx Biopharma and brings further R&D leadership experience from Pfizer, where he served as vice president for neurosciences.
Dr Pande currently serves on the board of directors for Karuna Pharmaceuticals – part of PureTech Health – as well as Axovant Sciences, Autifony Therapeutics, and Cennerv Pharma’s scientific advisory board.
Daphne Zohar, chief executive officer of PureTech Health, said: “We are excited to work more closely with Atul and to have access to his drug development expertise across PureTech Health’s pipeline.
“Atul is a seasoned drug development veteran who will help to shepherd our advancing pipeline through mid- and late-stage clinical trials while ensuring that synergies are leveraged across our platforms.”